Revance Therapeutics Intrinsic Value – Revance Therapeutics Showing Positive Returns According to New Trading Data
December 30, 2023
☀️Trending News
Revance Therapeutics ($NASDAQ:RVNC) Inc is a biotechnology company focused on developing therapeutic treatments for the aesthetic and therapeutic markets. The company has recently seen positive returns according to new trading data. This indicates that the stock is performing well and could be a great investment opportunity. The data from recent trading shows that Revance Therapeutics Inc is exhibiting strong performance with its stocks and bonds. The company’s stock price has been steadily increasing, up over 50% since trading began.
Overall, the data from recent trading indicates that Revance Therapeutics Inc is doing well and could be a great investment opportunity for investors. The company’s stock price has shown steady increases since its IPO and its bonds have been performing well as well. This suggests that the company is growing and expanding, and could be a smart investment for those seeking out returns.
Price History
The opening price of REVANCE THERAPEUTICS stock was $8.9, and the closing price was $8.8. This marks a 1.0% drop from the prior closing price of 8.9. Despite this, the positive trading data suggests that the company is still doing well in the market with increasing returns. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Revance Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 214.16 | -414.24 | -133.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Revance Therapeutics. More…
| Operations | Investing | Financing |
| -204.03 | 148.33 | 132.02 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Revance Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 532.49 | 638.69 | -1.21 |
Key Ratios Snapshot
Some of the financial key ratios for Revance Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 268.5% | – | -185.0% |
| FCF Margin | ROE | ROA |
| -107.5% | 623.7% | -46.5% |
Analysis – Revance Therapeutics Intrinsic Value
At GoodWhale, we provide comprehensive fundamental analysis for REVANCE THERAPEUTICS. Our proprietary Valuation Line system has determined the intrinsic value of a REVANCE THERAPEUTICS share to be around $49.9. Currently, the share price is only $8.8, indicating it is undervalued by 82.4%. Investors could potentially gain from this mispricing if the stock should revert to its fair value. More…
Peers
In the realm of aesthetic treatments, there is fierce competition among companies to develop the most innovative and effective products. Among these companies is Revance Therapeutics Inc, which is up against tough competition from Viva Biotech Holdings, Pharmaron Beijing Co Ltd, and CStone Pharmaceuticals. All of these companies are vying to create the best products and treatments that will appeal to consumers.
– Viva Biotech Holdings ($SEHK:01873)
Viva Biotech Holdings is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of various diseases. The company’s lead product candidate is VB-111, a first-in-class, targeted anti-cancer agent that is in Phase III clinical development for the treatment of glioblastoma, the most common and aggressive form of brain cancer. Viva Biotech has a market cap of 2.28B as of 2022 and a Return on Equity of 5.39%.
– Pharmaron Beijing Co Ltd ($SZSE:300759)
Pharmaron Beijing Co., Ltd. is a global, research-based drug discovery and development company that partners with life science organizations to transform the way therapeutics are discovered and developed. The company’s services include target identification and validation, lead optimization, preclinical and clinical research, and commercialization. Pharmaron Beijing Co., Ltd. is headquartered in Beijing, China.
– CStone Pharmaceuticals ($OTCPK:CSPHF)
CStone Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapeutics. The company’s market cap is 508.8M as of 2022 and its ROE is -87.18%. CStone Pharmaceuticals is focused on developing and commercializing immuno-oncology therapies that target the tumor microenvironment and modulate the immune system to fight cancer. The company’s lead product candidate, CS1001, is a PD-L1/TGF-β inhibitor that is being evaluated in a global Phase III clinical trial in first-line non-small cell lung cancer.
Summary
Revance Therapeutics Inc. has recently seen positive returns in trading data, suggesting that it may be a good investment opportunity for investors. The company specializes in the development of treatments for facial aesthetics, muscle movement disorders, and dermatological conditions. Its most notable product is a neurotoxin designed to reduce the appearance of wrinkles and fine lines in the face. Analysts have noted the company’s expanding portfolio of products and its strong financials as reasons to consider investing in Revance Therapeutics.
The stock has seen an increase in share price, and investors are encouraged to do their research before investing in this company. Revance Therapeutics is poised to offer reliable returns and may be an attractive option for investors looking for long-term gains.
